SIRT3 and COVID-19: Finally, the recent evidence that lower SIRT3 levels may be associated with a worst prognosis in patients with COVID-19, a disease that appears to share several pathological mechanisms with SSc, further supports the potential use of serum SIRT3 as an indicator of SSc-related pulmonary disease severity [38,43,44].